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Abstract 150 words 
Gene therapy uses genetic material as a drug delivery vehicle to express therapeutic 
proteins.  Placental gene therapy may be useful for correction of two important 
obstetric conditions, fetal growth restriction and pre-eclampsia in which there is a 
failure of the physiological trophoblast remodeling of the uterine spiral arteries in 
early pregnancy. The patient in this scenario is the fetus.  Placental gene therapy 
might be justifiable when (a) there is reasonable certainty that the fetus will suffer 
irreversible and substantial harm without the intervention, (b) the intervention is safe 
and effective, (c) the risk to the health of the mother is negligible and (d) the mother 
can give informed consent to the intervention.  
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Introduction 
The practice of obstetrics is rich in ethical considerations pertaining to the 
fetus and the mother. In no other specialty is the clinician carrying out risky 
procedures on one person with the aim of benefitting a (legal) non-person contained 
within.  Who is their patient?  Where does their duty of care lie?  The status of the 
fetus, the autonomy of the pregnant woman and the relationship between the two 
creates clinical, ethical and legal dilemmas.  New therapies are being introduced that 
highlight these ethical issues, and gene therapy is one such. This review addresses the 
ethical issues that arise when considering gene therapy to the placenta for treatment of 
genetic or placental disease.  
Placental gene therapy 
Gene therapy uses genetic material as a drug delivery vehicle to facilitate 
expression of therapeutic proteins.  Vectors such as manipulated viruses, are used to 
carry to the genes to the target cell or organ, where they use the cellular machinery to 
express the protein.  An increasing number of clinical trials show that for certain 
diseases, such as severe combined immunodeficiencies for example, postnatal gene 
therapy is efficacious.   
Pre-clinical studies in animals show that delivery of gene therapy to the fetus 
can provide a long term cure of single gene disorders, such as haemophilia, although 
clinical studies in H. Sapiens have yet to be done.  Attempting to treat the fetus by 
giving gene therapy to the mother’s circulation or into the placenta however, has so 
far not been shown to be successful.  Only low levels of vector reach the fetus and the 
placenta is a highly effective barrier to vector transfer.  Developments in vector 
design however may open the way to treat genetic disease in the fetus in the future.   
Placental gene therapy may be useful for correction of two important obstetric 
conditions, fetal growth restriction (FGR) and pre-eclampsia, that are major causes of 
maternal and neonatal morbidity and death worldwide.  The underlying abnormality is 
a failure of the physiological trophoblast remodeling of the uterine spiral arteries into 
low pressure, passively dilated channels conducting blood to the intervillous space 
that normally results in the huge increase in uterine perfusion from early pregnancy.  
Growth factors implicated in the pathogenesis of this uteroplacental insufficiency 
include Vascular Endothelial Growth Factor (VEGF), Insulin Growth Factor (IGF) 
and Placental Growth Factor (PlGF).  Over-expressing VEGF protein using gene 
therapy in the uteroplacental circulation increases uterine artery blood flow, and 
causes vasodilatation and new vessel formation, all of which may ameliorate the 
underlying abnormality in FGR and pre-eclampsia.  In this situation the aim is to treat 
the mother in order to benefit the fetus.  It is the uterine arteries and the maternal side 
of the placental circulation that is the target in placental gene therapy. This is different 
to the more usual case in which the fetus is directly given treatment to cure a fetal 
condition via the mother’s uterus, although the ethical issues are very similar.   
Justification for placental gene therapy 
The 1992 report of the Clothier committee recommended that gene therapy 
should be limited to life-threatening diseases or disorders for which no current 
alternative effective treatments are available.  The Gene Therapy Advisory 
Committee (GTAC) was established in 1993 to oversee and implement gene therapy 
clinical research.  In its 1998 report GTAC took account of ethical and safety issues 
relating to the potential use of gene therapy in the fetus in utero, and concluded that it 
was unlikely to be acceptable for the foreseeable future.  Gene therapy directed to the 
placenta however, was not specifically considered.   
Complications of growth restriction are concentrated in fetuses weighing 
around 500 gms or less, where growth velocity is reduced from an early gestation, and 
the fetus is sufficiently small to be nonviable if delivered, or associated with high 
postnatal mortality (>50%) and morbidity rates. When there is documented evidence 
from serial ultrasound scans that fetal growth has ceased completely and the weight 
remains below 500 gms the only management options currently available are to 
terminate the pregnancy, await inevitable fetal death in utero, or, if the fetus is 
between 450 and 500 gms, perform a caesarean section with a high chance of 
postnatal death or disability, and the usual risks to the mother associated with 
caesarean section. It is clear that even for normally grown fetuses born very 
premature, small increases in fetal growth and gestation at birth, such as a birthweight 
of 700g, or reaching 28 weeks of gestation, are associated with major improvements 
in survival and morbidity.  It is in this extreme, but not uncommon, scenario (approx 
2:1000 pregnancies), where no other therapies are available, that placental gene 
therapy to improve uterine blood flow might be both ethically acceptable and 
clinically relevant.  
Fetal issues 
 Intuitively, the patient in the placental gene therapy scenario is the fetus.  This 
is because the primary intention of the therapy is to promote growth of the fetus by 
improving placental function, in the hope of improving postnatal outcomes for the 
fetus.  Considering the fetus as a patient, and the potential conflict that presents to the 
mother and her clinician, is at the very core of the ethical issues in placental gene 
therapy. Advances in fetal medicine, ultrasound and neonatal care in particular have 
supported a changing view of the fetus.  When a neonate born at 23 weeks may 
survive and enjoy a good quality of life, then it may be argued that there is little 
difference in moral status between a late-gestation fetus and a newborn baby.  The 
obstetrician has a duty of care to the mother, and it has been argued, a duty to the 
fetus because it is potentially a born baby. Key to this concept of obligation to the 
fetus is the concept of viability, which states that there is a distinction between the 
‘pre-viable’ fetus and the ‘viable’ fetus.  The argument continues that the pre-viable 
fetus can only be considered a patient if the mother confers such a status on it whereas 
the ‘viable’ fetus is always regarded as a patient.   
This concept of viability has several problems. Viability is not fixed during 
gestation but depends on a number of factors such as the technological skill available, 
gestational age, birthweight and the presence of fetal abnormalities and indeed, 
placental gene therapy would aim to alter the viability status of the fetus.  The fetus at 
any stage of gestation is dependent on its mother and only becomes an independent 
person when it is separated from the materno-placental unit at birth.   
The ‘fetus-as-a-patient’ concept can create ethical conflict between the 
clinician and the mother, should she refuse a diagnostic or therapeutic intervention 
that the clinician considers to be beneficial to the fetus. Further, the duty of the 
clinician is firstly to ‘do no harm’ (principle of non-maleficence) and secondly ‘do the 
best for their patient’ (principle of beneficence). It is ultimately the mother who must 
decide what is in the best interests of her fetus, to give informed consent to any 
proposed intervention, and to also refuse treatment if she so wishes.  
English law gives absolute priority to the mother’s rights over that of the fetus 
she carries.  The mother’s decision is likely to depend on concerns for her family and 
other children, financial, psychosocial or religious factors. The autonomy of the 
mother is particularly important when the outcome of placental gene therapy can be 
uncertain.  It is possible that an intervention might be of partial benefit to the fetus, by 
saving its life, but result in the birth of a baby with a severe condition leading to its 
suffering and death within a few months. This arguably is a worse outcome than if the 
baby had not been born alive. The choice of termination of pregnancy to prevent 
suffering in the offspring remains available to parents before birth even if treatment 
fails, but not after birth. 
Gene transfer to the germline is a potential risk of placental gene therapy.  The 
GTAC subgroup on New and Emerging Technologies (NETS) considered that 
germline interventions are ‘off limits at present’  in agreement with the Clothier 
committee principles. Germline gene transfer has been observed after pre-clinical 
studies in large animals and depends on the gestational age and route of injection. It is 
unlikely that placental gene therapy would pose a risk to the germline because 
compartmentalization of the primordial germ cells would already have occurred by 
the time of the intervention, and the fetus would be exposed to very low levels of 
vector.  Nevertheless it is an issue that will need careful study including 
transgenerational pre-clinical animal studies before translating therapy into man.  
Maternal issues 
The argument that the fetus, viable or otherwise, should be considered as the, 
or a, patient is controversial, and as noted above is not the position taken in English 
law.  Nevertheless, obstetricians and pregnant women alike frequently do proceed on 
the assumption that the fetus is a patient, and one whose interests are of central 
concern. It is also possible, and perhaps desirable, to argue that it is the woman herself 
who is the primary, if not sole, patient.  Certainly the law and research ethics 
principles assume that it is her consent which is crucial (and in passing, we may note 
that the father’s consent is not relevant in law, even if it may be important in practice). 
Two issues are central here: the need for the autonomous consent of the woman as 
someone under going a risky (and at this stage experimental) procedure.  Second, we 
need to consider whether the woman’s interests are promoted (as required by the 
principle of beneficence) by the treatment.  Many many women have a strong interest 
in maintaining the pregnancy.  Where they do so, they have an interest in increasing 
the chances that the baby when born will be healthy. The decision to seek to maintain 
a pregnancy in the situation where placental gene therapy may be considered will 
necessarily be a difficult and highly personal one. 
A core principle governing gene therapy recommended by the Clothier 
committee, was that patients should take part in gene therapy research trials only after 
a full explanation of the procedures, risks and benefits and after they have given their 
informed consent, if they are capable of doing so.  The time available to parents to 
consider an intervention for FGR is likely to be short, because of the rapidly 
increasing demands that the fetus places on the uteroplacental circulation, and the 
difficulty in predicting early in pregnancy which fetuses are likely to be affected.  
Counseling should be independent and non-directive.  This is difficult when the 
alternatives are termination of pregnancy or almost certain neonatal death. 
Nevertheless, care must be taken to ensure that a placental gene therapy intervention 
is not presented coercively as an option to avoid a termination of pregnancy. The 
range of possible outcomes for the pregnancy should be understood by the parents. A 
team of consulting professionals is needed to consider the justification for 
intervention and to ensure the best outcome for the fetus and the mother’s immediate 
and long term health including any future children.   
Delivering placental gene therapy 
There must be a balance between the safety and the risk to the mother for 
delivery of placental gene therapy.  In some ways the intervention needs to be as safe 
as the alternatives, namely letting the fetus demise in utero or terminating the 
pregnancy, both of which carry a low risk of harm.  Allowing the pregnancy to 
continue might be harmful if the mother has also developed co-existing pre-
eclampsia, and the intervention failed to treat this.  The uteroplacental circulation 
could be targeted using minimally invasive interventional radiology techniques, such 
as those used to place catheters in the uterine arteries prior to Caesarean section in the 
presence of major placenta previa.  It would be critical to maintain sufficient uterine 
artery blood flow to the fetus during delivery of the gene therapy since a small, 
compromised fetus may be easily harmed by small reductions in substrate and oxygen 
supply.  It is clear that much pre-clinical work is needed in this area. 
Ethical issues in translating research into the clinic 
Regulatory procedures will need to be satisfied before human application 
could be attempted. This will involve lengthy toxicological animal studies including 
trans-generational experiments. Phase I human trials might also face hurdles because 
of difficulties in testing pregnant women where toxicological studies are usually 
contraindicated. Lifelong follow up of the mother and fetus is advocated in the 
context of prenatal gene transfer.  
A hypothetical treatment 
Assuming that a safe and effective placental gene therapy approach was to be 
possible, how might it work in practice for treatment of FGR?  Uteroplacental 
insufficiency can be suspected in the first trimester of pregnancy but more commonly 
is picked up at the anomaly scan that is commonly performed at 20 -22 weeks of 
gestation. Other causes of FGR would need to be sought and excluded, and the 
diagnosis of uteroplacental insufficiency confirmed two weeks later.  After the 
intervention, sonography could be used to monitor fetal wellbeing and growth 
according to usual fetal medicine practices.  There remain the options of terminating 
the pregnancy or awaiting fetal demise should the placental gene therapy fail.  
 
Practice Points 
 Delivering genes to the placenta may be useful for correction of obstetric 
conditions such as severe fetal growth restriction or pre-eclampsia that affect 
the uteroplacental circulation. 
 The patient in the placental gene therapy scenario is the fetus.  
 Placental gene therapy might be justifiable when there is reasonable certainty 
that the fetus will suffer irreversible and substantial harm without the 
intervention 
 The intervention will need to be safe and effective, with negligible risk to the 
health of the mother and where the mother can give informed consent.   
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